Alger Capital Appreciation Fund et al v. BioMarin Pharmaceutical Inc. et al: Complaint (‘Investment Fraud’)

Complaint “to recover significant investment losses suffered as a result of numerous false and misleading statements and omissions made by Defendants” in Alger Capital Appreciation Fund, Alger Mid Cap Growth Fund, Alger Health Sciences Fund, Alger Spectra Fund, Alger Dynamic Opportunities Fund, Alger Capital Appreciation Institutional Fund, Alger Focus Equity Fund, Alger Mid Cap Growth Institutional Fund, Alger Capital Appreciation Portfolio, Alger Midcap Growth Portfolio, Alger Collective Trust Spectra Series, Alger SICAV – Alger Dynamic Opportunities Fund, of Luxembourg; Alger SICAV – Alger American Asset Growth Fund, of Luxembourg; Alger SICAV – Alger Focus Equity Fund, of Luxembourg; Alger Capital Appreciation Series CIT, and Alger Capital, LLC v. BioMarin Pharmaceutical Inc., Jean-Jacques Bienaime, and Henry J. Fuchs at the U.S. District Court for the Northern District of California.


  • 107
    February 23, 2023
    BioMarin Pharmaceutical Inc., Jean-Jacques Bienaime, Henry J. Fuchs
    Alger Capital Appreciation Fund, Alger Mid Cap Growth Fund, Alger Health Sciences Fund, Alger Spectra Fund, Alger Dynamic Opportunities Fund, Alger Capital Appreciation Institutional Fund, Alger Focus Equity Fund, Alger Mid Cap Growth Institutional Fund, Alger Capital Appreciation Portfolio, Alger Midcap Growth Portfolio, Alger Collective Trust Spectra Series, Alger SICAV - Alger Dynamic Opportunities Fund, Alger SICAV - Alger American Asset Growth Fund, Alger SICAV - Alger Focus Equity Fund, Alger Capital Appreciation Series CIT, Alger Capital LLC
    Xx Xx Xx
    Fraud
    Robert Charles Ward, Rolnick Kramer Sadighi